These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 35882111)

  • 21. A Novel MVA-Based HIV Vaccine Candidate (MVA-gp145-GPN) Co-Expressing Clade C Membrane-Bound Trimeric gp145 Env and Gag-Induced Virus-Like Particles (VLPs) Triggered Broad and Multifunctional HIV-1-Specific T Cell and Antibody Responses.
    Perdiguero B; Sánchez-Corzo C; Sorzano COS; Saiz L; Mediavilla P; Esteban M; Gómez CE
    Viruses; 2019 Feb; 11(2):. PubMed ID: 30781504
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reducing V3 Antigenicity and Immunogenicity on Soluble, Native-Like HIV-1 Env SOSIP Trimers.
    Ringe RP; Ozorowski G; Rantalainen K; Struwe WB; Matthews K; Torres JL; Yasmeen A; Cottrell CA; Ketas TJ; LaBranche CC; Montefiori DC; Cupo A; Crispin M; Wilson IA; Ward AB; Sanders RW; Klasse PJ; Moore JP
    J Virol; 2017 Aug; 91(15):. PubMed ID: 28539451
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Selected HIV-1 Env trimeric formulations act as potent immunogens in a rabbit vaccination model.
    Heyndrickx L; Stewart-Jones G; Jansson M; Schuitemaker H; Bowles E; Buonaguro L; Grevstad B; Vinner L; Vereecken K; Parker J; Ramaswamy M; Biswas P; Vanham G; Scarlatti G; Fomsgaard A;
    PLoS One; 2013; 8(9):e74552. PubMed ID: 24023951
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Conformational States of a Soluble, Uncleaved HIV-1 Envelope Trimer.
    Liu Y; Pan J; Cai Y; Grigorieff N; Harrison SC; Chen B
    J Virol; 2017 May; 91(10):. PubMed ID: 28250125
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunization of rabbits with highly purified, soluble, trimeric human immunodeficiency virus type 1 envelope glycoprotein induces a vigorous B cell response and broadly cross-reactive neutralization.
    Quinnan GV; Onabajo O; Zhang P; Yan L; Mattapallil JJ; Zhang Z; Dong M; Lu M; Montefiori D; LaBranche C; Broder CC
    PLoS One; 2014; 9(5):e98060. PubMed ID: 24846288
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A New Approach to Produce HIV-1 Envelope Trimers: BOTH CLEAVAGE AND PROPER GLYCOSYLATION ARE ESSENTIAL TO GENERATE AUTHENTIC TRIMERS.
    AlSalmi W; Mahalingam M; Ananthaswamy N; Hamlin C; Flores D; Gao G; Rao VB
    J Biol Chem; 2015 Aug; 290(32):19780-95. PubMed ID: 26088135
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Generation of HIV-1 Virus-Like Particles expressing different HIV-1 glycoproteins.
    Visciano ML; Diomede L; Tagliamonte M; Tornesello ML; Asti V; Bomsel M; Buonaguro FM; Lopalco L; Buonaguro L
    Vaccine; 2011 Jul; 29(31):4903-12. PubMed ID: 21596074
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rapid Induction of Multifunctional Antibodies in Rabbits and Macaques by Clade C HIV-1 CAP257 Envelopes Circulating During Epitope-Specific Neutralization Breadth Development.
    Malherbe DC; Wibmer CK; Nonyane M; Reed J; Sather DN; Spencer DA; Schuman JT; Guo B; Pandey S; Robins H; Park B; Fuller DH; Sacha JB; Moore PL; Hessell AJ; Haigwood NL
    Front Immunol; 2020; 11():984. PubMed ID: 32582155
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structural and immunogenicity studies of a cleaved, stabilized envelope trimer derived from subtype A HIV-1.
    Kang YK; Andjelic S; Binley JM; Crooks ET; Franti M; Iyer SP; Donovan GP; Dey AK; Zhu P; Roux KH; Durso RJ; Parsons TF; Maddon PJ; Moore JP; Olson WC
    Vaccine; 2009 Aug; 27(37):5120-32. PubMed ID: 19567243
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clade C HIV-1 Envelope Vaccination Regimens Differ in Their Ability To Elicit Antibodies with Moderate Neutralization Breadth against Genetically Diverse Tier 2 HIV-1 Envelope Variants.
    Burton S; Spicer LM; Charles TP; Gangadhara S; Reddy PBJ; Styles TM; Velu V; Kasturi SP; Legere T; Hunter E; Pulendran B; Amara R; Hraber P; Derdeyn CA
    J Virol; 2019 Apr; 93(7):. PubMed ID: 30651354
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Membrane Env Liposomes Facilitate Immunization with Multivalent Full-Length HIV Spikes.
    Leaman DP; Stano A; Chen Y; Zhang L; Zwick MB
    J Virol; 2021 Jun; 95(13):e0000521. PubMed ID: 33883221
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structure-based design of native-like HIV-1 envelope trimers to silence non-neutralizing epitopes and eliminate CD4 binding.
    Kulp DW; Steichen JM; Pauthner M; Hu X; Schiffner T; Liguori A; Cottrell CA; Havenar-Daughton C; Ozorowski G; Georgeson E; Kalyuzhniy O; Willis JR; Kubitz M; Adachi Y; Reiss SM; Shin M; de Val N; Ward AB; Crotty S; Burton DR; Schief WR
    Nat Commun; 2017 Nov; 8(1):1655. PubMed ID: 29162799
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Presenting native-like HIV-1 envelope trimers on ferritin nanoparticles improves their immunogenicity.
    Sliepen K; Ozorowski G; Burger JA; van Montfort T; Stunnenberg M; LaBranche C; Montefiori DC; Moore JP; Ward AB; Sanders RW
    Retrovirology; 2015 Sep; 12():82. PubMed ID: 26410741
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Breadth of neutralizing antibodies elicited by stable, homogeneous clade A and clade C HIV-1 gp140 envelope trimers in guinea pigs.
    Nkolola JP; Peng H; Settembre EC; Freeman M; Grandpre LE; Devoy C; Lynch DM; La Porte A; Simmons NL; Bradley R; Montefiori DC; Seaman MS; Chen B; Barouch DH
    J Virol; 2010 Apr; 84(7):3270-9. PubMed ID: 20053749
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HIV transmitted/founder vaccines elicit autologous tier 2 neutralizing antibodies for the CD4 binding site.
    McCurley NP; Domi A; Basu R; Saunders KO; LaBranche CC; Montefiori DC; Haynes BF; Robinson HL
    PLoS One; 2017; 12(10):e0177863. PubMed ID: 29020058
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Murine Antibody Responses to Cleaved Soluble HIV-1 Envelope Trimers Are Highly Restricted in Specificity.
    Hu JK; Crampton JC; Cupo A; Ketas T; van Gils MJ; Sliepen K; de Taeye SW; Sok D; Ozorowski G; Deresa I; Stanfield R; Ward AB; Burton DR; Klasse PJ; Sanders RW; Moore JP; Crotty S
    J Virol; 2015 Oct; 89(20):10383-98. PubMed ID: 26246566
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunogenic Display of Purified Chemically Cross-Linked HIV-1 Spikes.
    Leaman DP; Lee JH; Ward AB; Zwick MB
    J Virol; 2015 Jul; 89(13):6725-45. PubMed ID: 25878116
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biochemical and immunogenic characterization of soluble human immunodeficiency virus type 1 envelope glycoprotein trimers expressed by semliki forest virus.
    Forsell MN; Li Y; Sundbäck M; Svehla K; Liljeström P; Mascola JR; Wyatt R; Karlsson Hedestam GB
    J Virol; 2005 Sep; 79(17):10902-14. PubMed ID: 16103142
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Envelope proteins of two HIV-1 clades induced different epitope-specific antibody response.
    Shrivastava T; Samal S; Tyagi AK; Goswami S; Kumar N; Ozorowski G; Ward AB; Chakrabarti BK
    Vaccine; 2018 Mar; 36(12):1627-1636. PubMed ID: 29429810
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sequential immunizations with a panel of HIV-1 Env virus-like particles coach immune system to make broadly neutralizing antibodies.
    Mohan T; Berman Z; Kang SM; Wang BZ
    Sci Rep; 2018 May; 8(1):7807. PubMed ID: 29773829
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.